Cancer BiologybioRxivPreprint
ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition
J. E. Ferguson, H. Rehman, D. S. Chandrashekar…·S. Varambally
This study shows that ARID1A-deficient bladder cancer cells are sensitive to EZH2 inhibition, suggesting a therapeutic strategy for patients with ARID1A mutations.
DOI 10.1101/2021.01.12.426383